Claims for Patent: 7,994,220

Summary for Patent: 7,994,220

Title:	Milnacipran for the long-term treatment of fibromyalgia syndrome
Abstract:	The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.
Inventor(s):	Rao; Srinivas G. (Encinitas, CA), Gendreau; Michael (Poway, CA), Kranzler; Jay D. (La Jolla, CA)
Assignee:	Cypress Bioscience, Inc. (San Diego, CA)
Application Number:	11/535,237
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,994,220
Patent Claims:	1. A method of treating fibromyalgia in a patient suffering from fibromyalgia comprising administering milnacipran, or a pharmaceutically acceptable salt thereof, to the patient according to the following schedule: a) administering 12.5 mg milnacipran/day to the patient for 1 day; then b) administering 25 mg milnacipran/day to the patient for 2 days; then c) administering 50 mg milnacipran/day to the patient for 4 days; then d) administering 100 mg milnacipran/day. 2. The method of claim 1, wherein the milnacipran or a salt thereof is administered in a tablet dosage form. 3. The method of claim 2, wherein the tablet dosage form comprises an amount of milnacipran selected from 12.5 mg, 25 mg, 50 mg, or 100 mg. 4. The method of claim 1, wherein the milnacipran in steps b) to d) is administered twice daily. 5. The method of claim 1, wherein the milnacipran in step b) is administered as a 12.5 mg dosage two times per day. 6. The method of claim 1, wherein the milnacipran in step c) is administered as a 25 mg dosage two times per day. 7. The method of claim 1, wherein the milnacipran in step d) is administered as a 50 mg dosage two times per day.